Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START Protocols: Long Term Safety and Efficacy Analysis.
Read time: 1 mins
Last updated:12th Oct 2007
The primary objective is to determine the long term safety and tolerability of dasatinib. The secondary objective of this study is to collect long term efficacy in terms of molecular response.
|Study start date||2007-10-12|